Michelle Gillespie, Olufunke Afolabi-Brown, Evans Machogu, Shaina Willen, Benjamin T. Kopp
Ohio State University Wexner Medical Center and Nationwide Children’s Hospital.Children’ Hospital of Philadelphia. Riley Hospital for Children and Indiana University School of Medicine. University of California Davis Medical Center. Children’s Healthcare of Atlanta.
United States
Clinics in Chest Medicine
Clin Chest Med 2024; 45: 749-760
DOI: 10.1016/j.ccm.2024.02.022
Abstract
Sickle cell lung disease presents a challenging care paradigm involving acute and chronic lower airway disease, sleep-disordered breathing, pulmonary vascular disease, and modification by environmental factors. Understanding the presentation, pathophysiology, and diagnostic approaches is essential for accurate identification and management. While significant progress has been made, there remains a need for research to develop effective treatments and interventions to decrease disease burden in these children. Additionally, the long-term impact of interventions on cardiopulmonary outcomes is unknown. Collaborative efforts among health care providers, researchers, advocacy groups, and policy makers are crucial to improving the lives of children with SCD.
Category
Class V. Pulmonary Hypertension Associated with Hematological, Systemic, Metabolic and Other Disorders
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: No